2. Search Result
Search Result
Results for "

NaPi2

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145894
    NaPi2b-IN-2

    		Others Others
    NaPi2b-IN-2 (compound 5) is a potent inhibitor of sodium-dependent transport protein 2b (SLC34A2, NaPi2b), with an IC50 of 38 nM for human NaPi2b. NaPi2b-IN-2 can be used for the research of hyperphosphatemia .
    <em>NaPi2</em>b-IN-<em>2</em>
  • HY-112065
    PF-06869206
    1 Publications Verification

    		 Sodium Channel Metabolic Disease
    PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM .
    PF-06869206
  • HY-P99229
    Upifitamab

    		ADC Antibody Cancer
    Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .
    Upifitamab
  • HY-146429
    NaPi2b-IN-3

    		Others Metabolic Disease
    NaPi2b-IN-3 (compound 5) is a potent sodium-dependent transport protein 2b (SLC34A2, NaPi2b) inhibitor with IC50s of 71 nM and 28 nM for human NaPi2b and rat NaPi2b, respectively. NaPi2b-IN-3 can be used for researching hyperphosphatemia .
    <em>NaPi2</em>b-IN-3
  • HY-142957
    NaPi2b-IN-1

    		Others Others
    NaPi2b-IN-1 is a potent and orally active inhibitor of sodium-dependent phosphate transport protein 2b (NaPi2b) with an IC50 of 64 nM. NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. NaPi2b-IN-1 has the potential for the research of hyperphosphatemia .
    <em>NaPi2</em>b-IN-1
  • HY-P99970
    Lifastuzumab

    		ADC Antibody Others
    Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .
    Lifastuzumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: